Jacob Funds Bets on Prime Medicine (PRME), a Next-Generation Gene Therapy Company
Jacob Funds, in its Q4 2025 investor letter, highlighted Prime Medicine, Inc. (NASDAQ:PRME) as a new investment, expressing confidence in its next-generation gene therapy technology. The fund believes Prime Medicine's elegant and precise gene editing function could offer simpler and safer treatment options for various diseases. Despite the early stage of development, promising efficacy and safety signals from its first clinical trial fueled Jacob Funds' decision to invest.
Prime Medicine, Inc. (NYSE:PRME) Receives Average Recommendation of "Moderate Buy" from Brokerages
Seven brokerages have issued a "Moderate Buy" consensus rating for Prime Medicine, Inc. (NYSE:PRME), with an average 12-month price target of $7.21. The clinical-stage gene-editing company focuses on developing single-dose treatments for various diseases using its proprietary prime editing technology. Shares recently opened at $3.57 and saw a 10.2% increase, with institutional investors holding a significant portion of the stock.
Institutional Owners May Ignore Prime Medicine, Inc.'s (NASDAQ:PRME) Recent US$66m Market Cap Decline as Longer-term Profits Stay in the Green
Institutional investors, who hold 45% of Prime Medicine, Inc. (NASDAQ:PRME), may not be significantly concerned by the recent US$66m market cap decline due to strong longer-term returns. While they experienced an 8.9% drop last week, the company's one-year returns of 44% likely offset these losses. Key shareholders include institutions, private equity firms (20%), and insiders like David Liu, who holds 11% and is a top key executive, indicating alignment with shareholder interests.
Institutional investors in Prime Medicine, Inc. (NASDAQ:PRME) see US$110m decrease in market cap last week, although long-term gains have benefitted them.
Institutional investors in Prime Medicine, Inc. (NASDAQ:PRME) experienced a US$110 million decrease in market cap last week, but still benefited from 36% one-year gains. Institutions hold a significant 44% ownership in the company and are the largest group of shareholders. The top 8 shareholders collectively own more than half the company's shares, with insiders also holding a substantial stake.
Institutional investors in Prime Medicine, Inc. (NASDAQ:PRME) see US$110m decrease in market cap last week, although long-term gains have benefitted them.
Institutional investors in Prime Medicine, Inc. (NASDAQ:PRME) experienced a US$110m decrease in market cap last week, despite having benefited from 36% one-year gains. Institutions hold a significant 44% ownership in the company, making its stock price sensitive to their trading actions. The top 8 shareholders combined own 52% of the business, with insider ownership at 15%.
Institutional investors in Prime Medicine, Inc. (NASDAQ:PRME) see US$110m decrease in market cap last week, although long-term gains have benefitted them.
Institutional investors in Prime Medicine, Inc. (NASDAQ:PRME) experienced a US$110 million decrease in market cap last week, despite having benefited from 36% gains over the past year. Institutions hold 44% of the company, making its stock price sensitive to their trading actions, with the top 8 shareholders controlling 52% of the business. Insiders own 15%, while private equity firms hold 20% and the general public 15%.
JonesTrading Maintains Prime Medicine(PRME.US) With Buy Rating, Maintains Target Price $5
JonesTrading analyst Soumit Roy has reaffirmed a "buy" rating for Prime Medicine (PRME.US), maintaining a target price of $5. This analyst, according to TipRanks data, has a 27.5% success rate and an average return of -12.9% over the past year. The information is provided for informational purposes and does not constitute investment advice.
Prime Medicine (NASDAQ:PRME) Shares Up 10.5% - Here's Why
Prime Medicine (NASDAQ:PRME) saw its shares climb 10.5% during Thursday's trading session, reaching a high of $4.52 before settling at $4.43. This occurred despite the company reporting an earnings per share miss of ($0.32) against a consensus of ($0.28) and maintaining a negative net margin of -3,301.64%. Analyst sentiment is split, with one "Strong Buy" and one "Sell" rating, resulting in a "Moderate Buy" consensus for the biotechnology firm.
Sumitomo Mitsui Trust Group Inc. Boosts Stake in Prime Medicine, Inc. $PRME
Sumitomo Mitsui Trust Group Inc. significantly increased its stake in Prime Medicine, Inc. (NYSE:PRME) by 127.7% in the third quarter, now owning 3,629,924 shares valued at approximately $20.11 million. Institutional investors collectively hold about 70.37% of the company's stock. Analysts currently rate Prime Medicine as a "Moderate Buy" with an average price target of $7.21, although individual targets show a wide range.
Prime Medicine (NASDAQ:PRME) Trading Down 7.9% - Should You Sell?
Prime Medicine (NASDAQ:PRME) saw its shares drop 7.9% to $3.97 on Thursday, with trading volume significantly below average. The company faces mixed analyst ratings, ranging from "strong-buy" to "sell," resulting in a "Moderate Buy" consensus from MarketBeat. Financially, Prime Medicine reported weak fundamentals in its latest quarter, including missed EPS estimates, low revenue, and a very negative net margin.
Prime Medicine (NASDAQ:PRME) Shares Up 8.4% - Should You Buy?
Prime Medicine (NASDAQ:PRME) saw its shares jump 8.4% to $4.51 during mid-day trading on Wednesday, though with lower-than-average volume. Analyst opinions are divided, with Lifesci Capital upgrading it to a "strong-buy" while Weiss Ratings and Wall Street Zen downgraded it to "sell," leading to a "Moderate Buy" consensus on MarketBeat. The company reported a wider-than-expected quarterly EPS loss and low revenue, reflecting negative margins as it continues to develop its Prime Editing gene-therapy platform.
Prime Medicine updates corporate strategy for Prime Editing platform
Prime Medicine (PRME) has announced an updated corporate strategy for its Prime Editing platform, detailing clinical and regulatory timelines for its programs in liver, lung, and oncology indications. The company plans to file regulatory applications and initiate Phase 1 trials for liver-focused candidates PM577 and PM647 in 2026, with initial clinical data expected in 2027. Prime Medicine aims to expand its pipeline organically and through partnerships, leveraging its gene-editing technology for broad therapeutic potential.
Prime Medicine, Inc. Updates on Prime Editing Developments
Prime Medicine, Inc. has provided updates on its Prime Editing technology, detailing advancements and anticipated milestones for 2026. The company expects to file IND/CTA applications for Wilson Disease and AATD in the first half and mid-2026, respectively, and shared positive early Phase 1/2 data for its CGD treatment. Prime Medicine's platform is projected to address over 90% of genetic diseases, with potential for significant milestones from a partnership with Bristol Myers Squibb.
Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference
Prime Medicine, Inc. announced that CEO Allan Reine, M.D., will present a corporate overview at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The presentation will cover the company's proprietary Prime Editing platform, a versatile gene editing technology focused on developing one-time curative genetic therapies. A live audio webcast will be available on the company’s website, with a replay accessible for 90 days.
Prime Medicine (NYSE:PRME) Trading Down 3.3% - Here's What Happened
Prime Medicine (NYSE:PRME) experienced a 3.3% drop in its stock price during mid-day trading, with a significant decline in trading volume. This comes amidst mixed analyst ratings, with some firms maintaining bullish price targets while Citigroup cut its target to $4.25, leading to a consensus "Moderate Buy" rating. The company, a clinical-stage genetic medicines firm, has a market capitalization of $610.49 million, and institutional investors collectively own 70.37% of the stock.
LifeSci Capital Initiates Prime Medicine (PRME), Highlights One-and-Done Potential in Liver and Lung Diseases
LifeSci Capital initiated coverage on Prime Medicine (PRME) with an Outperform rating and a $6 price target, citing the company's "one-and-done" gene editing treatments for conditions like Wilson’s disease, alpha-1 antitrypsin deficiency, and cystic fibrosis. Separately, Prime Medicine announced the publication of successful Phase 1/2 clinical data for its investigational therapy, PM359, used to treat p47phox chronic granulomatous disease, demonstrating the safety and efficacy of Prime Editing. The trial results showed rapid neutrophil and platelet engraftment and sustained clinical improvement in two patients.
LifeSci Capital Initiates Prime Medicine (PRME), Highlights One-and-Done Potential in Liver and Lung Diseases
LifeSci Capital initiated coverage on Prime Medicine (PRME) with an Outperform rating and a $6 price target, citing the company's "one-and-done" gene editing treatments for conditions like Wilson's disease and alpha-1 antitrypsin deficiency/AATD. This follows Prime Medicine's announcement of Phase 1/2 clinical data for PM359 in the New England Journal of Medicine, demonstrating the safety and efficacy of its Prime Editing technology for p47phox chronic granulomatous disease. The article highlights the potential of Prime Medicine's gene editing technology to address high unmet medical needs.
Prime Medicine, Inc. (PRME) Announces NEJM Publication Of PM359 Data
Prime Medicine, Inc. announced the publication of Phase 1/2 clinical results for PM359 in the New England Journal of Medicine, an experimental autologous hematopoietic stem cell therapy for p47phox chronic granulomatous condition. Preliminary data from two patients showed fast neutrophil engraftment and no new CGD-related problems or adverse events linked to PM359. LifeSci Capital initiated coverage on Prime Medicine with an Outperform rating and a $6 price target, citing the company's potential in gene editing treatments for various diseases.
Prime Medicine, Inc. (PRME) Announces NEJM Publication Of PM359 Data
Prime Medicine, Inc. (NASDAQ:PRME) announced the New England Journal of Medicine has published Phase 1/2 clinical results for PM359, its experimental autologous hematopoietic stem cell therapy for p47phox chronic granulomatous condition. The preliminary data showed promising safety and biological function in two patients, with rapid neutrophil engraftment and no severe adverse events linked to PM359. LifeSci Capital initiated coverage on Prime Medicine with an Outperform rating and a $6 price target, citing optimism about the company's gene-editing treatments for various diseases.
Lifesci Capital Predicts Prime Medicine FY2025 Earnings
Lifesci Capital projects Prime Medicine's FY2025 EPS at ($1.41) and maintains an "Outperform" rating with a $6.00 price target, which is more optimistic than the consensus estimate of ($1.68). Institutional investors showed significant interest in Q3, with Farallon Capital Management LLC and ARK Investment Management LLC substantially increasing their stakes, indicating strong investor confidence. The stock currently holds a "Moderate Buy" consensus rating from analysts, with an average target price of $7.21.
Prime Medicine (NYSE:PRME) Stock Price Down 4.2% - Should You Sell?
Prime Medicine (NYSE:PRME) saw its stock price drop 4.2% on Wednesday, with significantly lower trading volume than average. Despite the decline, analysts maintain a "Moderate Buy" consensus rating with an average price target of $7.21, and institutional ownership remains high, with major firms increasing their stakes in the last quarter.
Prime Medicine (NASDAQ:PRME) Upgraded at Lifesci Capital
Lifesci Capital upgraded Prime Medicine (NASDAQ:PRME) to a "strong-buy" rating, despite the company missing quarterly EPS estimates, posting low revenue, and having significant negative margins and return on equity. The stock opened at $3.69 with a 52-week range of $1.11–$6.94 and a market cap of approximately $666 million. Other firms have issued "sell" ratings, and the overall consensus from MarketBeat is a "Moderate Buy."
Prime Medicine, Inc. (NYSE:PRME) Given Consensus Rating of "Moderate Buy" by Brokerages
Prime Medicine, Inc. (NYSE:PRME) has received a consensus "Moderate Buy" rating from six brokerages, with three analysts recommending "hold" and three recommending "buy." The average 12-month price target is $7.45, although recent adjustments include Chardan cutting its target to $9, Wedbush at $8, and Citi lowering its target to $4.25. Institutional investors hold 70.37% of the stock, and the company focuses on developing CRISPR-derived prime editing therapies for various genetic disorders.
Asked and Answered: Prime Medicine CEO on First Prime Editing Patient Data
Prime Medicine CEO Allan Reine discusses the implications of promising initial patient data from a prime editing treatment for chronic granulomatous disease (CGD) on the company's clinical roadmap. Despite the success, Prime Medicine is pausing active recruitment for the CGD trial due to market size, redirecting focus to larger opportunities in liver, lung diseases, and immune-system cancers, while actively pursuing collaborations and advancements in prime editing technology. Reine emphasizes the goal of expanding prime editing's reach to more diseases and patients through strategic resource allocation and partnerships.
Prime Editing Clinical Results Published for the First Time Ever
In a landmark study, researchers have published the first peer-reviewed clinical results of prime editing in human patients, successfully treating two individuals with p47phox-deficient chronic granulomatous disease (p47-CGD). The PM359 therapy effectively corrected a two-base pair deletion in NCF1 using prime editing, leading to restored immune function and no new disease-related complications for the patients. Despite the clinical success, Prime Medicine is winding down its CGD program due to the small market size, shifting focus to other diseases with larger patient populations.
Prime Medicine's Market Cap Up US$161m Following Year Of Insider Stock Buying
Prime Medicine, Inc. (NASDAQ:PRME) saw its market capitalization increase by US$161 million, following a 28% stock rise that rewarded insiders who bought shares over the last year. These insiders realized a 263% gain on their initial US$283.9k investment. The CEO made a significant purchase, and insiders collectively own 15% of the company, indicating confidence in its future.
Prime Medicine's Market Cap Up US$161m Following Year Of Insider Stock Buying
Prime Medicine (NASDAQ:PRME) saw its market capitalization increase by US$161m after its stock rose 28%, resulting in a 263% gain for insiders who bought shares over the past year. The CEO and Director, Allan Reine, made a significant purchase of US$147k worth of shares at a price significantly below the current market value. Insiders collectively own 15% of the company, valued at US$112m, indicating confidence in Prime Medicine's future.
Prime Medicine (NASDAQ:PRME) Shares Gap Up - Still a Buy?
Prime Medicine (NASDAQ:PRME) saw its shares gap up on Monday, opening at $3.98 after closing at $3.74, and trading at $3.85 with a volume of approximately 594,508. Despite this gain, the stock remains below its 50-day simple moving average of $4.69. Wall Street sentiment is predominantly negative, with multiple firms issuing "sell" ratings and the company reporting weak fundamentals, including an EPS miss and negative net margin.
Prime Medicine's Market Cap Up US$161m Following Year Of Insider Stock Buying
Prime Medicine, Inc. (NASDAQ:PRME) saw its market capitalization increase by US$161 million, a 28% rise, after a year of insider stock buying. Insiders' initial US$283.9k investment is now worth US$1.03 million, representing a 263% gain. The CEO's significant purchase at a lower price suggests a belief in the stock's undervaluation, and high insider ownership (15%, worth US$112m) indicates confidence in the company's future.
Prime Medicine’s Stock Fluctuations: How Genomic Advances Steer Performance
Prime Medicine Inc. (PRME) experienced a 10.29% stock increase following successful Phase 1/2 clinical trial results for PM359, a gene therapy for Chronic Granulomatous Disease. The company's financial health shows significant R&D investment and potential for long-term growth despite challenges like regulatory scrutiny and market volatility inherent in the gene therapy sector. This rise in stock highlights investor confidence spurred by scientific breakthroughs as Prime Medicine navigates a complex and speculative market.
Prime Medicine announces NEJM publication of PM359 data
Prime Medicine (PRME) announced the publication of Phase 1/2 clinical data for PM359 in the New England Journal of Medicine (NEJM), an investigational autologous hematopoietic stem cell product for p47phox chronic granulomatous disease (CGD). The data, also to be presented at the 67th American Society of Hematology (ASH) Annual Meeting, reports initial results for two patients. These patients showed rapid neutrophil engraftment, were free of new CGD-related complications, and experienced no clinically significant adverse events attributable to PM359.
Prime Medicine (Nasdaq: PRME) reports first-in-human PM359 CGD data in NEJM study
Prime Medicine announced the publication of Phase 1/2 clinical data for PM359 in The New England Journal of Medicine, detailing its use as an investigational autologous HSC product for p47phox chronic granulomatous disease (CGD). Two patients in the study showed rapid neutrophil and platelet engraftment, durable NADPH oxidase activity, and early clinical benefits without significant adverse events attributed to PM359. These results highlight the potential of Prime Editing as a precise and safe therapeutic strategy for CGD and were also presented at the 67th ASH Annual Meeting.
Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease
Prime Medicine, Inc. announced the publication of Phase 1/2 clinical data for PM359, its investigational product for p47 phox chronic granulomatous disease (CGD), in the New England Journal of Medicine. The study showed that two patients experienced rapid neutrophil and platelet engraftment, durable restoration of NADPH oxidase activity, and early clinical benefit without significant safety concerns, marking the first in-human demonstration of Prime Editing's safety and efficacy. These results highlight Prime Editing's potential as a precise therapeutic strategy for CGD and its advantages over other gene editing technologies.
Prime Medicine, Inc. (PRME) Reports Q1 Loss, Misses Revenue Estimates
Prime Medicine, Inc. (PRME) announced a Q1 loss of $0.40 per share, missing the Zacks Consensus Estimate of a $0.32 loss, and reported revenues of $1.45 million, falling short of estimates by 68.25%. Despite underperforming the market year-to-date with a 51.4% stock decline, the company currently holds a Zacks Rank #3 (Hold), suggesting it is expected to perform in line with the market. Investors are advised to monitor management's commentary and future earnings expectations, with consensus EPS for the next quarter at -$0.31 and revenues at $4.58 million.
Prime Medicine to Present at 8th Annual Evercore Healthcare Conference
Prime Medicine, Inc. announced that CEO Allan Reine, M.D., will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 2, 2025. The company specializes in developing gene editing therapies using its proprietary Prime Editing platform. A live audio webcast and replay will be available on Prime Medicine’s website.
Prime Medicine Bets On Gene Editing’s Next Big Leap
Prime Medicine (PRME) is a clinical-stage biotechnology company focused on developing gene therapies using its proprietary Prime Editing platform, which offers a potentially safer and more versatile approach than traditional CRISPR. The company faces significant financial hurdles and market volatility but is poised for key clinical readouts and regulatory filings, attracting investor interest despite its high valuation and lack of commercial revenue. Its future hinges on successful trial results and strategic partnerships to de-risk its innovative technology.
Institutional investors in Prime Medicine, Inc. (NASDAQ:PRME) see US$174m decrease in market cap last week, although long-term gains have benefitted them.
Institutional investors in Prime Medicine, Inc. (NASDAQ:PRME) experienced a US$174m decrease in market capitalization last week. Despite this recent dip, their long-term gains have been positive. Institutions hold 30% ownership, indicating significant influence, with the top 8 shareholders controlling over half the company's shares.
Prime Medicine, Inc. (PRME) Reports Q3 Loss, Lags Revenue Estimates
Prime Medicine, Inc. (PRME) reported a Q3 loss of $0.32 per share, missing the Zacks Consensus Estimate of $0.28, and revenues of $1.23 million, which also fell short of expectations. Despite the financial misstep, the company's shares have risen 43.2% year-to-date, outperforming the S&P 500. The stock currently holds a Zacks Rank #3 (Hold), indicating it is expected to perform in line with the market.
Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates
Prime Medicine announced its Q3 2025 financial results and provided business updates, highlighting progress in its gene-editing pipeline. The company is advancing liver-targeted programs for Wilson’s Disease (PM577) and Alpha-1 Antitrypsin Deficiency (PM647), with new preclinical data for PM577 to be presented at AASLD and IND/CTA filings expected in 2026 and 2027 respectively. Prime Medicine also strengthened its leadership and reported a net loss of $50.6 million for the quarter, with a cash position of $227.0 million expected to fund operations into 2027.
Head to Head Review: Prime Medicine (NYSE:PRME) & Genocea Biosciences (NASDAQ:GNCAQ) - Defense World
This article provides a head-to-head comparison of Prime Medicine (NYSE:PRME) and Genocea Biosciences (NASDAQ:GNCAQ), evaluating their valuation, earnings, analyst ratings, profitability, volatility, risk, and institutional/insider ownership. Prime Medicine appears more favorable due to stronger analyst ratings and higher potential upside, despite Genocea Biosciences having higher earnings but lower revenue. The article also provides company overviews, noting Genocea Biosciences' recent Chapter 11 liquidation.
Painful Week for Retail Investors Invested in Prime Medicine, Inc. (NASDAQ:PRME) After 6.6% Drop, Institutions Also Suffered Losses - 富途牛牛
Prime Medicine, Inc. (NASDAQ:PRME) experienced a 6.6% drop last week, impacting both retail investors (30% ownership) and institutional investors (28% ownership). While retail investors hold the largest share, significant stakes are also held by institutions, private equity, and public companies, with insiders owning 15% and a top executive holding 12%. The article emphasizes the importance of considering various shareholder groups and analyst recommendations for a comprehensive understanding of the company's future performance.
Prime Medicine Soars 9.88% to Day High of $6.85 Amid Strong Intraday Performance - Markets Mojo
Prime Medicine, Inc. saw a significant intraday gain of 9.88%, reaching a day high of $6.85, contributing to its impressive year-to-date return of 120.89%. Despite facing financial challenges like negative EBITDA and a net loss, the company recorded robust net sales growth and high institutional holdings. The article highlights Prime Medicine's strong market performance compared to the S&P 500, along with its paradoxical financial metrics.
Prime Medicine to Participate in Upcoming Investor Conferences
Prime Medicine, Inc. announced its management will participate in two virtual and in-person investor conferences in October 2025: the H.C. Wainwright Genetic Medicines Virtual Conference and Chardan’s 9th Annual Genetic Medicines Conference. The company will discuss its Prime Editing platform, which aims to develop one-time curative genetic therapies, and its diversified portfolio of therapeutic programs.
PRME, TWST, TEM: Cathie Wood Pours $1.9M Into Biotech, Cuts Stake in AI Stock
Cathie Wood's ARK Invest recently invested $1.9 million into biotech companies Prime Medicine (PRME) and Twist Bioscience (TWST), demonstrating continued confidence in the sector. Concurrently, ARK trimmed its position in the AI-driven health-tech company Tempus (TEM), selling approximately $2.08 million worth of shares. This move suggests profit-taking in Tempus, which has seen a significant surge, and a reallocation of capital towards biotech.
Prime Medicine, Inc. (PRME) Reports Q2 Loss, Lags Revenue Estimates
Prime Medicine, Inc. (PRME) reported a Q2 loss of $0.41 per share, missing the Zacks Consensus Estimate of a $0.36 loss, and revenues of $1.12 million, falling short of estimates by 59.6%. Despite this, the stock has gained 39.4% year-to-date and currently holds a Zacks Rank #2 (Buy), indicating potential for future outperformance. The company belongs to the Medical - Biomedical and Genetics industry, which is performing well.
Prime Medicine, Inc. Announces Pricing of $125.4 Million Public Offering of Common Stock
Prime Medicine, Inc. has announced the pricing of a public offering for 38 million shares of common stock at $3.30 per share, aiming to raise approximately $125.4 million in gross proceeds. The offering is expected to close around August 1, 2025, with TD Cowen and BMO Capital Markets acting as joint book-running managers. The company plans to use these funds to further develop its gene editing therapies, focusing on areas like liver, lung, and oncology diseases.
Prime Medicine, Inc. (PRME) Now Trades Above Golden Cross: Time to Buy?
Prime Medicine, Inc. (PRME) has recently experienced a "golden cross" event, where its 50-day simple moving average crossed above its 200-day simple moving average, signaling a potential bullish breakout. The stock has rallied 40.3% in the past four weeks and holds a #2 (Buy) on the Zacks Rank, further supported by positive earnings outlook with increased Zacks Consensus Estimate. Investors are advised to monitor PRME for potential continued gains due to this technical indicator and strong fundamentals.
Cystic Fibrosis Foundation Commits Up to an Additional $24 Million for Prime Medicine to Develop Gene Editing Therapy
The Cystic Fibrosis Foundation announced an additional investment of up to $24 million in Prime Medicine to advance a gene editing therapy for cystic fibrosis, specifically targeting the G542X nonsense mutation. This funding will support preclinical research and efforts to overcome delivery challenges to the lungs. The collaboration aims to develop a permanent correction for CF-causing mutations using Prime Medicine's gene editing technology.
Pharma Boom: Prime Medicine’s Stocks Surge
Prime Medicine Inc.'s stocks surged by 13.17% following favorable gene-editing technology advancements and promising clinical trial data. Despite significant net losses due to aggressive R&D spending, the company maintains a solid balance sheet and high liquidity, positioning it as a leader in biopharmaceutical research. This market response highlights investor optimism for groundbreaking treatments, even amidst financial complexities.
Gene-Editing Biotech Prime Medicine Strikes Up Cell Therapy R&D Alliance With Bristol Myers Squibb
Prime Medicine has partnered with Bristol Myers Squibb (BMS) in an R&D alliance focused on developing next-generation cell therapies for cancer and immunology using Prime Medicine's gene-editing technology. BMS will pay $110 million upfront and could provide over $3.5 billion in milestone payments, plus royalties. This collaboration, along with a pipeline reprioritization, extends Prime Medicine's capital runway into the first half of 2026.
